Patent: 8,703,150
✉ Email this page to a colleague
Summary for Patent: 8,703,150
| Title: | Methods of using Bacillus anthracis protective antigen sequences for vaccination |
| Abstract: | The invention relates to improved methods of producing and recovering B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax. |
| Inventor(s): | Leppla; Stephen H. (Bethesda, MD), Schneerson; Rachel (Bethesda, MD), Robbins; John B. (New York, NY) |
| Assignee: | The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) N/A (N/A) |
| Application Number: | 13/244,060 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,703,150
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Emergent Biodefense Operations Lansing Llc | BIOTHRAX | anthrax vaccine adsorbed | Injection | 103821 | 11/12/1998 | ⤷ Try a Trial | 2021-11-09 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
